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Abstract 
 
 
It is known that pituitary PRL secretion is modified in patient with primary 
hypothyroidism, and that hyperprolactinaemia can occur.  The objective of this 
study was to verify the presence of hyperprolactinaemia in Sudanese hypothyroid 
patients and to evaluate the effect of L-thyroxine therapy in normalizing high PRL 
levels. 
Forty four patients with primary hypothyroidism were studied.  patients of both 
sexes and all ages were included, (33 females and 11 males, aged 1 to 85 years). 
Diagnosis was based on clinical features and plasma T4 (mean 16 nmol/l; N.R. = 
64 to 154 nmol/l), and TSH (mean = 112 mU/I; N.R. = 0.5 to 3.5 mU/I) levels.  
PRL determinations (N.R. 0 to 360 mU/l) were made using immunoradiometric 
assay. 
Nineteen patients were found to have high PRL (range 400 to 1959 mU/l; mean = 
877 mU/I). Hypothyroid patients with high PRL undersent a second test after L-
thyroxine replacement therapy (100 – 200 ug/d) had led to euthyroidism. 
Plasma PRL levels fell dramatically (mean = 395 mU/I) in all patients who had an 
initial high PRL. 
In conclusion this study shows that hyperprolactinaemia is common (43% of cases) 
in primary hypothyroidism and that it is correctable with L-thyroxine therapy. 
It is essential that thyroid function tests are performed on every patient with 
hyperprolactinaemia. 
 
 
 
 
  ﺧﻼﺻﺔ ﺍﻻﻃﺮﻭﺣﺔ
ﻘﺼﻮﺭ ﺍﻟﻐﺪﺓ ﺍﻟﺪﺭﻗﻴﺔ ﺍﻻﻭﱄ ﻭﳝﻜﻦ ﺍﻥ ﻳﺴﺒﺐ ﺯﻳﺎﺩﺓ ﺍﳍﺮﻣﻮﻥ ﻣﻦ ﺍﳌﻌﺮﻭﻑ ﺍﻥ ﺍﻓﺮﺍﺯ ﺍﳍﺮﻣﻮﻥ ﺍﻟﻠﺒﲏ ﻣﻦ ﺍﻟﻐﺪﺓ ﺍﻟﻨﺨﺎﻣﻴﺔ ﻳﺘﻐﲑ ﰲ ﺍﳌﺮﺿﻲ ﺑ
  .ﺍﻟﻠﺒﲏ ﰲ ﺍﻟﺪﻡ 
 ﺯﻳﺎﺩﺓ ﺍﳍﺮﻣﻮﻥ ﺍﻟﻠﺒﲏ ﰲ ﺍﻟﺪﻡ ﰲ ﻣﺮﺿﻲ ﻗﺼﻮﺭ ﺍﻟﻐﺪﺓ ﺍﻟﺪﺭﻗﻴﺔ ﺍﻟﺴﻮﺩﺍﻧﻴﲔ ﻭﺗﻘﻴﻴﻢ ﺗﺄﺛﲑ ﺍﳍﺪﻑ ﻣﻦ ﻫﺬﻩ ﺍﻟﺪﺭﺍﺳﺔ ﻫﻮ ﺍﺧﺘﺒﺎﺭ ﻭﺟﻮﺩ
  .ﺪﻝ ﺍﻟﻄﺒﻴﻌﻲ ﺍﻟﻌﻼﺝ ﺑﺎﻟﺜﺎﻳﺮﻭﻛﺴﲔ ﰲ ﺍﺭﺟﺎﻉ ﺍﳌﻌﺪﻻﺕ ﺍﻟﻌﺎﻟﻴﻪ ﻟﻠﻬﺮﻣﻮﻥ ﺍﻟﻠﺒﲏ ﺍﱄ ﺍﳌﻌ
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  .ﺫﻛﺮ 
ﻗﺼﻮﺭ ﺍﻟﻐﺪﺓ ﺍﻟﺪﺭﻗﻴﺔ ﰲ ﻫﺆﻻﺀ ﺍﳌﺮﺿﻲ ﰎ ﺑﻨﺎﺀ ﻋﻠﻲ ﺍﻻﻋﺮﺍﺽ ﺍﻟﺴﺮﻳﺮﻳﺔ ﻭﻋﻠﻲ ﻣﻌﺪﻻﺕ ﺍﻟﺜﺎﻳﺮﻭﻛﺴﲔ ﰲ ﺍﻟﺪﻡ ﻭﻋﻠﻲ ﻣﻌﺪﻻﺕ ﺗﺴﺨﻴﺺ 
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THE THYROID GLAND 
 
Anatomy: The Thyroid is one of the largest of the endocrine organs 
weighing approximately 20 g in adults.  Moreover, the potential of the gland 
for growth is tremendous.  Goiters weighing many hundreds of gms are not 
rare. 
The gland is well vascularized.  Estimates of thyroid blood flow range from 4 
to 6 ml/min/g, well in excess of the blood flow to the kidney (3 ml/min/g). 
With light microscopy, the gland is seen to be composed of closely packed 
sacs, called acini or follicles, which are invested with a rich capillary 
network.  The interior of the follicle is filled with the clear proteinaceous 
colloid, which normally is the major constituent of the total thyroid mass. 
 
The wall of the follicle is lined by a single layer of cuboidal cells.  The cell 
height of the acinar epithelium varies with the degree of glandular 
stimulation, becoming columnar when active and flat when inactive. 
 
With the electron microscopy, there are numerousmicrovilli extending into 
the colloid from the apical aspect of the follicular cell.  It is at or near this 
surface of the cell iodination, exocytosis, and  the initial phase of hormone 
secretion occur(1).  
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Synthesis and Secretion of Thyroid Hormones: 
Thyroglobulin, a specific thyroprotien, is the major component of the 
intrafollicular colloid. 
 
The metabolism of iodide leading to the biosynthesis of thyroid hormones 
occur in three sequential stages: 
1. Active transport of iodide into the thyroid. 
2. oxidation of iodide and iodination of tyrosyl residues within 
thyroglobulin to yield the hormonally, inactive iodotyrosines MIT 
and DIT. 
3. oxidative condensation of iodotyrosines to form the hormonally 
active iodothyronines notably T4 and T3. 
 
The hormones thus formed are held in peptide linkage within the 
thyroglobulin. 
Release of hormones involves two additional groups of reactions: 
1. Hydrolysis of thyroglobulin by a thyroid protease and by 
peptidases, liberating free iodinated amino acids. 
2. passage of iodothyronines into the blood. 
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The activity of the iodide transport mechanism is influenced by a variety of 
physiological factors, the most important of which is the level of TSH 
stimulation.  
 
The other major factor that influences iodide transport is an internal 
autoregulatory system through which the intrinsic activity of the iodide 
transport mechanism and its responsiveness to TSH stimulation vary 
inversely with the glandular content of organic iodine(2). 
 
Storage and Release of Thyroid Hormones: 
 
Thyroglobulin is the storage form of the thyroid hormone.  The thyroid is 
unique among the endocrine glands by virtue of the large store of hormone it 
contains, and the slow overall rate at which the hormone normally turns over.  
This aspect of thyroid hormone economy has homeostatic value in that the 
large hormone reservoir provides prolonged protection against depletion of 
circulating hormone should synthesis cease(3). 
 
The sequence where by proteolytic cleavage of thyroglobulin to liberate T3 & 
T4 is best observed after stimulation of the resting thyroid by TSH(4).  Within 
a few minutes after such stimulation, formation of pseudopodia is evident at 
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the apical surface of the follicular cell, followed by endocytosis of colloid to 
yield multiple vesicles (colloid droplets). 
 
Concomitantly with endocytosis, lysosomes migrate from the basal toward 
the apical end of the cell. Fusion of lysosomes with colloid droplets occurs 
resulting in phagolysosomes where hydrolysis of thyroglobulin takes place 
and that leads to liberation of T3 and T4.  the process of proteolysis and 
release of thyroid hormones are inhibited by several agents, most important is 
iodine(1). 
 
Transport, Turnover and Metabolsim of Thyroid Hormones: 
 
A wide variety of iodothyronines and their metabolic derivatives exist in 
plasma.  Of these, T4 is the highest in concentration and is the only one that 
arises solely by direct secretion from the thyroid gland, but most of the T3 in 
the plasma is derived from the peripheral tissues, where it is generated by 
enzymatic removal of a single iodine atom (monodeiodination) from T4, the 
remaining iodothyronines and their derivates are almost entirely generated in 
the peripheral tissues from T4 & T3. 
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Upon entering the blood the major secretary products of the normal thyroid 
gland, T4, T3, as well as the products of peripheral T4 and T3 metabolism, 
are bound in a firm but reversible bond to several proteins, all of which are 
synthesized in the liver.  The two plasma proteins with which T4 is mainly 
associated are thyronine-binding globulin (TBG) and T4-binding prealbumin 
(TBPA).  To a limited extent, T4 is also bound to albumin; T3  is bound 
mainly by TBG and to a small extent, by albumin. 
 
TBG is normally responsible for transport of most of the T4 (about 77%) and, 
with the serum T4 concentration, is the major determinant of the free T4.  
TBPA plays a lesser role, except when TBG is lacking. 
 
As a result of their interaction with the transport proteins, the iodinated 
amino-acids acquire macromolecule properties that alter their metabolism.  
The negligible urinary excretion of T4 and T3 is almost certainly due to the 
limited filterability of the hormone-binding protein complexes at the 
glomerulus.  The volume of distributin and rate of turnover of the hormones 
are also affected by their protein association. 
T4 and T3 exist in the plasma in both the bound and free forms, and it is 
possible to measure the free T4 and free T3 by direct radioimmunoassay(5). 
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In normal serum, the free T4 is approximately 0.03% of the total, (about 2 
ng/dl).  The affinity of TBG for T3 is tenfold lower than for T4, this results in 
a proportion of fT3 of approximately 0.3% of the total, that is about ten times 
that of T4. 
 
It is the free hormone that is available to the tissues and that can induce 
metabolic effects and undergo degradiation.  The bound form of the hormone 
acts merely as a metabolically inert reservoir. 
 
The proportion of free hormone is inversely related to the concentration of 
unoccupied binding sites and their binding affinity for the hormone in 
question.  In the presence of an increase in the overall net binding affinity for 
T4, a normal T4 concentration can be mainainted only if the bound T4 
concentration increases.  This is true whether the causative factor is an 
increase in the concentration of TBG or the appearance of abnormal T4 – 
binding proteins. 
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Circumstances associated with Alteration in binding of T4 by 
TBC: 
 
Increase binding to TBG:  1.  Pregnancy    2.  Neonatal State      3.  
Estrogens and hyperestrogemic state  4. Tamoxifen 5.  Oral Contraceptives       
6.  Acute intermittent porphyria 7.  Infections and chronic active 
hepatitis   8.  Billiary cirrhosis 9. Perphenazine. 
 
Decrease Binding:  1- Androgen or anabolic steroids   2-  Large doses 
of glucocorticoids 3-  Active acromegaly 4-  Nephrotic syndrome
 5-  Major systemic illness 6-  Asparaginase. 
 
About 35% of the T4 secreted in normal man is deiodinated to yield T3, and 
about 40% is deiodinated to yield rT3.  Hence with a normal T4 production 
rate of 90 ug daily, approximately 26 ug of T3 and 30 ug of rT3 are produced 
by peripheral deiodination.  When these values are compared with estimated 
total daily production rates for T3 and rT3, nearly all (at least 80%) of normal 
T3 production and all of rT3 production can be accounted for by peripheral 
conversion from T4, rather than direct thyroid secretion. 
Factors that impair peripheral conversion of T4 to T3: 
1. Physiological: Fetal and early neonatal life; old age. 
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2. Pathological:  Fasting; malnutrition; systemic illness; trauma; 
post-operative state. 
3. Pharmacological: Propylthiouracil; dexamethazone; propranolol; 
amiodarone; radiographic contrast agents. 
 
Physiological implications: 
In regard to thyromimetic actions, T3 is several times more active than T4, 
and rT3 is extremely inactive(6). 
 
Regulation of Thyroid Functions: 
 
The change in thyroid iodine and intermediary metabolism, size and 
histological features that accompany variations in the secretion of TSH 
suggest that TSH is the major regulator of thyroid structure and function. 
 
Regulation of TSH secretion results from complex interactions, mainly or 
entirely at the level of the pituitary thyrotropic cells, in which TRH acts to 
stimulate first, the release and later the synthesis of TSH, while thyroid 
hormones inhibit these functions. 
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TRH, a modified tripeptide, is synthesized by peptidergic neurons in the 
supraoptic and paraventricular nuclei of the hypothalamus, when it is 
transported to and storeed in the median eminence.  From here, TRH enters 
the hypophyseal portal venous system, in which it crosses the pituitary stalk, 
and is carried to the cells of the anterior pituitary gland. 
 
Thyrotropic and lactotropic cells contain specific saturable receptors to which 
TRH binds, eliciting a stimulation of adenylate cyclase.  Under the influence 
of TRH, secretion of TSH is promptly stimulated, enhanced synthesis of TSH 
follows. 
 
Pituitary tissue contains high affinity, limited capacity nuclear receptors for 
T3 and T4 through which feed back inhibition of TSH secretion is mediated. 
 
Although TRH and thyroid hormones are the major regulators of TSH 
secretion, other factors play a role as well.  Somatostatin (Growth hormone 
release – inhibiting factor) decreases the response to TRH.  Prolonged 
administration of levodopa decreases the basal serum TSH concentration in 
hypothyroid patients and decreases the response to TRH.  Similar effects 
follow dopamine infusion and the administration of bromocriptine, a 
stimulator of dopamine receptor(1). 
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Conversely, blockage of the dopamine receptor by metoclopramide increases 
the basal serum TSH concentration in both euthyroid and hypothyroid 
patients and increase the response to TRH(7).  These findings leave little doubt 
that dopamine is a physiological inhibitor of TSH secretion. 
TSH is a glycoprotein hormone secreted by the thyrotropic cells, located in 
the anteromedial portion of the adenohypophysis.  Removal of TSH 
stimulation is followed by hypovascularity and atrophy of the thyroid gland, 
accompanied by decreased synthesis and secretion of thyroid hormones, 
whereas, converse effects are produced by stimulatory dose of TSH. 
The development of sensitive and specific radio-immunoassays for TSH has 
made possible its measurement in serum. 
 
TSH is serum displays both episodic and circadian variation.  The former is 
characterized by fluctuations at one – to two – hour intervals, suggesting that 
TSH is secreted in a pulsatile manner.  The circadian variation is 
characterized by a nocturnal surge.  The circadian variation in TSH secretion 
does not appear to be related to change in TRH secretion, since it persists 
during prolonged TRH infusion, but may reflect instead fluctuation in 
dopaminergic inhibitor influences.  In patient with severe hypothyroidism, 
the circadian variation may disappear. 
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Effects of Thyroid Hormones on Metabolic Processes: 
 
The thyroid hormones play upon a great multiplicity of metabolic processes, 
influencing the concentration and activity of numerous enzymes; the 
metabolism of substrates, vitamins and minerals; the secretion and 
degradation rates of virtually all other hormones; and the response of their 
target tissues to them(8).  It can truly be said that no tissue or organ system 
escapes the adverse effects of thyroid hormone excess or insufficiency.  
 
HYPOTHYRODISM 
 
Hypothyroidism is a progressive disorder presenting with different degrees of 
thyroid failure and metabolic consequences.  Subcinical hypothyroidism, 
defined as a condition with normal circulating levels of T4 and T3 but 
elevated TSH(9),  is a common condition in the general population, affecting 
about 6% to 7.5% of females and 2.5% to 3% of males(10).  Overt 
hypothyroidism develops at a rate of 5% to 10% per year in such subjects(11). 
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Causes of Thyroid Hormone Deficiency: 
 
1) Loss or atrophy of thyroid tissue (Thyroprivic hypothyroidism): 
a. Primary iodiopathic hypothyroidism 
b. Thyroid aplasia or dysplasia 
c. Postablative hypothyroidism 
 
2) Insufficient stimulation of an intrinsically normal gland as a result 
of hypothalamic or pituitary disease (Trophoprivic 
hypothyroidism): 
a. Sheehan’s syndrome 
b. Infiltrative disorders of pituitary or hypothalamus. 
 
3) compensatory goitroges as a result of defective hormone 
biosynthesis (Goitrous hypothyroidism):  
a. Hashimotos thyroiditis 
b. Endemic iodine deficiency 
c. Antithyroid agents 
d. Heritable defect in hormone biosynthesis and action 
e. Peripheral resistance to thyroid hormone. 
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Of the three categories, thyroprivic and goitrous hypothyrodism together 
account for approximately 95% of cases. 
Peripheral Manifestations of Thyroid Hormone Deficiency: 
 
Skin and Appendages: 
 
In the dermis as well as in other tissues, an accumulation of hyaluronic acid 
alters the composition of the ground substance. 
 
This material binds water, producing the mucinous oedema that is responsible 
for the thickened features and fluffy appearance (termed myxoedema) of 
patients with full-blown hypothyroidism. 
 
Myxoedema is characteristically boggy and non pitting and is most apparent 
around the eyes, on the dorsa of the hands and feet, and in the supraclavicular 
fossae.  It causes enlargement of the tongue and thickening of the pharyngeal 
and laryngeal mucous membranes.  In addition the skin is pale and cool as a 
result of cutaneous vasoconstriction. 
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Anaemia commonly contributes to pallor, hypercarotenaemia gives the skin a 
yellow tint.  The secretions of the sweat glands and sebaceous glands are 
reduced, leading to dryness and coarseness of the skin. 
 
Head and body hair is dry and brittle.  Loss of hair from the temporal aspect 
of the eyebrows is common.  The nails are brittle and grow slowly. 
 
Cardiovascular system: 
 
The cardiac output at rest is decreased because of a reduction in both stroke 
volume and heart rate, reflecting loss of the inotropic and chronotropic effects 
of thyroid hormones. 
 
The decrease in cutaneous circulation is responsible for the sensitivity to 
cold. 
 
In thyroprivic hypothyroidism the heart is enlarged and the heart sounds are 
diminished in intensity.  These findings are due largely to effusion in the 
pericardial sac of fluid rich in protein and mucopolysaccharides,  but dilation 
of a “flabby” myocardium may also be a factor.  Pericardial effusion is rarely 
of a degree sufficient to case tamponade. 
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Angina pectoris is uncommon in hypothyroidism(1),  more commonly, angina 
either appears or is worsened during treatment of the hypothyroid state with 
thyroid hormones. 
 
ECG changes include sinus bradycardia, prolongation of the PR interval, low 
amplitude of the P wave and QRS complex, alteration of the ST segment, and 
flattened or inverted T waves.  Rarely, complete heart block may be 
present(12). 
 
Respiratory system: 
 
Pleural effusions are common(1).  These usually are evident only on 
radiological examination but rarely may be sufficient to cause dyspnoea. 
 
Alimentary system: 
 
Although most patients show a modest gain in weight the appetite is 
characteristically reduced.  Such weight gain as occurs is due largely to 
retention of fluid by the hydrophilic mucopolysaccharide deposits in the 
tissues. 
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Peristaltic activity is decreased and, together with the decreased food intake, 
is responsible for the frequent complaint of constipation. 
 
Ascites is unusual, but may occur, usually in association with pleural and 
pericardial effusions. 
 
Nervous system: 
 
Thyroid hormone is essential for the development of the CNS. 
 
Deficiency in fetal life or at birth results in retention of the infantile 
characteristics of the brain(13).   If deficiency is not corrected in early 
postnatal life, irreversible damage results.  Deficiency beginning in adult life 
causes  manifestation of lesser severity that usually respond to treatment.  
One of the characteristic features is a general slowing of all intellectual 
functions including speech.  There is loss of initiative.  Slow wittedness and 
memory defects are common. Headache occurs quite frequently.  Cerebral 
hypoxia resulting from circulatory alterations may predispose to confusional 
attacks, syncope and coma.  Hearing loss of perceptive type is frequent. 
 
 17
Thick, slurred speech and hoarseness are common and are due to 
myxoedematous infiltration of the tongue and larynx respectively.  
Movements are slow and clumsy and pronounced ataxia of cerebellar type 
may occur.  Carpal tunnel syndrome is frequent.  The tendon jerks are slow 
specially during the relaxation phase, producing the characteristic “hung-up 
reflexes” this phenomenon appears to result from a decrease in the rate of 
muscle contraction and relaxation rather than from a delay in nerve 
conduction. 
 
The concentration of protein in the CSF is often increased, but pressure is 
normal. 
 
Skeletal system: 
 
Thyroid hormone is essential for normal growth and maturation of the 
skeleton.  The effect on growth appears to be due to a stimulation of failure of 
ovulation.  Secretion of progesterone fails and endometrial proliferation 
persists, resulting in excessive and irregular menstrual bleeding.  These 
changes may be due to deficient secretion of LH(14,15). 
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In severe long standing thyroprivic hypothyroidism, secondary depression of 
pituitary function may occur, leading to ovarian atrophy and amenorrhoea.  
Fertility is reduced, and if conception does take place, abortion often results. 
In men hypothyroidism may be accompanied by diminished libido, 
impotence and oligospermia. 
 
Composite Clinical Picture of Hypothyroidism: 
Adult Hypothyroidism: 
 
The onset of hypothyroidism is usually so insidious that the classical clinical 
manifestation may take months or years to appear and frequently go 
unnoticed by persons well acquainted with the patient. 
 
The early symptoms of hypothyroidism are variable and non-specific. 
 
The following table shows the frequency of symptomatology of myxoedema 
in 77 cases (64 women and 13 men) in study done in 1948 by Means JH(16). 
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Symptoms % of cases Symptom % of cases 
Weakness 99 Constipation 61 
Dry skin 97 Gain in weight 59 
Coarse skin 97 Loss of hair 57 
Lethargy 91 Pallor of lips 57 
Slow speech 91 Dyspnoea 55 
Oedema of eyelids 90 Peripheral 
oedema 
55 
Sensation of cold 89 Hoarseness or 
aphonia 
52 
Decreased sweating  89 Anorexia 45 
Cold skin 83 Nervousness 35 
Thick tongue 82 Menorrhagia 32 
Oedema of face 79 Palpitation 31 
Coarseness of hair  76 Deafness 30 
Pallor of skin 67 Pericardial pain 25 
Memory impairment 66   
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Eventually, the picture of full-blown myxoedema results, with thickened 
features, enlarged tongue, hoarseness, non-pitting oedema and extreme 
mental and physical lethargy. 
 
The patient, if untreated, may remain in this state for year, finally developing 
myxoedema coma or succumbing to an interucrrent infection or vascular 
occlusion. 
 
Infantile Hypothyroidism and Cretinism: 
 
Hypothyroidism is seldom apparent at birth.  The age at which symptoms 
appear depends on the degree of impairment of thyroid function.  Severe 
hypothyroidism in infancy is termed cretinism. 
 
As the age of onset increases, the clinical picture of cretinism merges 
imperceptibly with that of juvenile hypothyroidism. 
 
Retardation of mental development and growth is the hallmark of cretinism.  
Since these changes become manifest only in late infancy and are by then 
largely irreversible, early recognition is crucial and can be achieved by 
routinely measuring serum T4 or TSH concentrations in the neonate. 
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During the first few months of life, symptoms of hypothyroidism include 
feeding problems, failure to thrive, constipation, a hoarse cry, and 
somnolence. 
 
In succeeding months, protuberance of the abdomen, dry skin, poor growth of 
hair and nails, and delayed eruption of deciduous teeth become evident.  
Linear growth is severely impaired, resulting in dwarfism.  The appearance is 
characteristic, with broad flat nose, widely set eyes, periorbital puffiness, 
large protruding tongue, sparse hair, rough skin, short neck, and protuberant 
abdomen with an umbilical hernia.  Mental deficiency is usually severe. 
 
Radiological examination of the skeleton is diagnostic.  The skull shows a 
poorly developed base, delayed closure of the fontanels, widely set orbits, 
and short flat nasal bone.  The pituitary fossa may be enlarged. 
 
The center of ossification appears late, and instead of a single center, multiple 
small centers are scattered through the epiphysis.  These small centers 
eventually coalesce, forming a single center that has an irregular outline and 
supplied appearance “Stippled Epiphysis”. 
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Hypothyroidism beginning in childhood is termed juvenile hypothyroidism.  
The clinical manifestations of this state are intermediate between those of 
infantile and adult hypothyroidism, in that the developmental retardation is 
not as severe as that of cretinism and the manifestations of full-blown adult 
myxoedema are rarely seen.   Eruption of permanent teeth is delayed, sexual 
maturation is retarded and the onset of puberty is delayed.  The result is a 
child who appears much younger than his chronological age. 
 
Differential Diagnosis: 
 
The clinical picture of fully developed myxoedema is usually characteristic 
enough to leave the diagnosis in little doubt. 
 
? In some elderly patients, slowing of mental and physical activity, dry 
skin, and loss of hair especially from the lateral third of the eyebrows, 
may mimic similar findings in hypothyroidism. 
? In patients with chronic renal failure, anaorexia, periorbital puffiness, 
sallow complexion and anaemia may suggest hypothyroidism. 
? The differentiation of nephrotic state from hypothyroidism is more 
difficult.  Here, waxy pallor, oedema, hypercholesterolaemia and 
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hypometabolism may suggest hypothyroidism.  In addition, significant 
loss of TBG results in decreased total T4 in nephrotic. 
? In pernicious anaemia psychiatric abnormalities, a lemon yellow tint of 
skin, and numbness and tingling of the extremities may mimic similar 
finding in hypothyroidism. 
? The presence of hypothyroidism is often suspected in patients who are 
severely ill, especially if they are elderly.  In ill patient T3 is almost 
invariably decreased owing to decreased peripheral generation of T3 
from T4.  In more severely ill patients, however, T4 is also decreased.  
The presence of normal free T4 together with the absence of elevated 
TSH concentration, serves to differentiate the severely ill but 
intrinisically euthyroid patient from the patient with thyroprivic 
hypothyroidism. 
? Down’s syndrome resembles cretinism in that both are accompanies by 
retardation of mental development and shortness of stature.  The 
differentiation of these two diseases is not difficult but subclinical or 
frank hypothyroidism and evidence of thyroid autoimmunity may be 
present in as many as 30% of patients with down’s syndrome(17). 
? Dwarfism resulting from cretinism or juvenile hypothyroidism differs 
from dwarfism of other causes such as hypopituitarism, rickets, and 
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achondroplasia, in that it is usually accompanied by mental retardation, 
retarded bone age, and epiphysial dysgenesis. 
? The differentiation of pituitary from thyroprivic hypothyroidism is 
important because, in the former, treatment with thyroid hormone 
alone fails to correct the associated endocrine abnormalities, and 
indeed, by precipitating acute adrenocortical insufficiency may be 
dangerous. 
 
Three major aspects serve to differentiate pituitary from thyroprivic 
hypothyroidism: 
 
1. Features arising from the cause of the pituitary insufficiency itselt, 
e.g. features of Sheehan’s syndrome, or pituitary tumours. 
2. difference in clinical manifestations where in pituitary 
hypothyroidism the changes in skin and its appendages are less 
striking, and depigmentation of the areolae frequently occurs, 
amenorrhoea rather than menorrhagia occurs and the breasts are 
atrophic.  The heart size is usually small and blood pressure is low.  
Further more, manifestations of hypoglycaemia may occur in 
pituitary hypothyroidism. 
3. differences in laboratory indices. 
 25
 
Investigation of Suspected Hypothyroidism: 
 
Measure plasma TSH levels and total T4 levels.  Normal values are: 
 
 CONTENTIONAL SI 
T4 5 to 12 µg/dl 64 to 154 nmol/L 
TSH 0.5 to 3.5 µU/ml 0.5 t 3.5 mU/L 
 
The lower limit of ‘normal’ for T4 is poorly defined.  Levels within the 
reference range may be suboptimal for that individual patient(18). 
Because of the T4-pituitary feedback, however, this will be established by the 
resultant increased TSH secretion.   
 
A very low plasma  T4 value indicates hypothyroidism unless there is gross 
TBG deficiency.  In most cases the TSH level will be high (primary 
hypothyroidism).  If it is low, proceed to a TRH test (see below). 
 
If the patients is very ill investigations should be deferred until the patient has 
recovered from the illness (sick euthyroid). 
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A borderline low T4 value with: 
(a) a slightly elevated TSH may indicate early hypothyroidism.  Measure 
circulating thyroid antibodies to assess the presence of autoimmune 
thyroiditis.  Note, however, that their presence does not confirm 
hypothyroidism.  As replacement treatment is probably not indicated at this 
stage, repeat the test after a period of 3 to 6 months. 
(b) a normal TSH value suggest either that there is competition by a drug for 
binding sites on TBG, or that hypothyroidism is secondary to pituitary or 
hypothalamic disease.  A slightly low T4 with a normal TSH may also 
be due to severe non-thyroidal disease.  Reassess the drug history.  If 
secondary hypothyroidism is suspected, proceed to a TRH test where: 
basal blood sample is taken, then 200 ug of TRH in 2 ml saline is 
injected intravenously over about a minute, and further blood samples 
are taken 20 and 60 minutes after the TRH injection.  TSH is measured 
in all samples.  In normal subject plasma TSH levels increase by at least 
2 mU/litre and exceed the upper limit of the reference range.  The 
maximum response occurs at 20 minutes.  A subnormal rise of TSH 
confirms the diagnosis of secondary hypothyroidism of pituitary origin. 
A normal response, or an exaggerated but delayed rise with TSH levels 
higher at 60 minutes than at 20 minutes suggests secondary hypothyroidism 
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due hypothalamic dysfunction.  If clinically indicated, pituitary and 
hypothalamic function should be investigated. 
 
T3 is not of much help in the diagnosis of dysfunction, because the thyroid 
that has not totally failed and that is being stimulated by high concentrations 
of TSH secretes with a high T3/T4 ratio.  Thus, in mild or moderate primary 
dysfunction, low levels of the serum T4 may be accompanied by an increased 
serum TSH concentration and by concentrations of T# that are near normal, 
normal or even elevated(1-19). 
 
The serum TSH concentration is invariably increased in patients with 
hypothyroidism of primary thyroid origin, the extent of increase correlating 
with the severity, but not the duration of the disease.  Hence, values may 
range from those, that are minimally elevated in very mild hypothyroidism to 
those that are is excess of 1000 mU/L in patients with severe disease(1). 
 
Other Biochemical Findings in Thyroid disease: 
 
The concentration in serum of several enzymes that apparently originate in 
skeletal muscle are usually elevated in hypothyroidism.  The enzymes 
principally affected are the MM variant of CPK, and less often LDH and 
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AST(20).  Such alterations are of negligible value in diagnosis of thyroid 
function. 
Hypercholesterolaemia has for a long time been recognized as a common 
laboratory finding in hypothyroidism.  A graded increase in the mean 
Treatment of hypothyroidism Page 25 not clear. 
 
Heart failure or myocardial infarction in the former, or may provoke relative 
adrenal insufficiency in the latter. 
Daily dose is increased by increment of 25 or 50 ug at two-to-three-weeks 
intervals until a normal metabolic state is attained(21).  The final maintenance 
dose required is in the range of 2.2 to 2.5 ug/kg body weight, or about 150 
ug/day.  Anyhow, the clinical state and T4 concentration are the best 
indicators of determining when the satisfactory dose has been achieved.  
Patient with hypothyroidism display a propensity to discontinue their 
medication when they are feeling better or when their supply of hormone is 
exhausted; this occurs even when they have been informed that treatment is 
required indefinitely. 
Infants and Children: 
If severe hypothyroidism did not begin in utero, the chances of normal 
intellectual development are good if vigorous treatment is begin before the 
age of 4 months. 
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In assessing the response to treatment in infancy, it is essentialthat attention 
be paid to the ages at which various milestones of development are attained.         
On a unit weight basis, infants and children require larger doses than do 
adults. 
Treatment is begun with a daily dose of 25 ug of levothyroxine, increased by 
increments of 25 ug at one week intervals, so that the infant is receiving a 
daily dose of 100 ug after 3-4 weeks.  Thereafter the daily dose is increased 
slowly so as to maintain serum T4 concentration between 9 and 12 ug/dl (116 
and 154 nmol/L). 
In the infant, intellectual development is the crucial guide to adequacy of 
treatment.  In older child, the rate of skeletal growth and maturation and the 
time of dental eruption and of sexual maturation are important guidelines in 
the treatment.  The maintenance dose for children ranging in age from 1 year 
to the midteens is about 3.5 ug/k body weight per day(22,23). 
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PROLACTIN 
 
The lactotrophs constitute 10 to 25 percent of the normal pituitary and 
increase to 70 percent during pregnancy.  Lactotrophs are located 
predominantly in the lateral wings of the pituitary gland.  Lactotrophs 
synthesize, store and secrete prolactin(24).  The human placental deciduas also 
synthesizes prolactine. 
 
Action: 
 
PRL acts directly on the mammary gland.  It has little role in mammogenesis 
but is responsible for the initiation and maintenance of lactation.  The action 
of PRL on lactation requires preparation of the breast tissue by oestrogens 
and progesterone. 
 
During pregnancy the combined effect of pituitary and placental 
mammotropic hormones, oestrogens and progesterone cause development of 
the secretary apparatus of the breast. 
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Actual lactation is inhibited in pregnancy by high levels of oestrogen and 
progesterone.  Following delivery, oestrogen and progesterone levels fall 
rapidly and the lactogenic action of PRL is unopposed. 
Regulation: 
 
The secretion of prolactin is suppressed by dopamine, which reaches the 
pituitary in portal venous blood.  Any interference with the portal circulation 
or blockade of hypothalamic dopamine release or action results in increased 
prolactin secretion is higher in women with normal ovarian function than in 
men.  This is the result of oestorgen action.  Marked stimulation of prolactin 
secretion is associated with pregnancy. 
Sucking is a potent stimulus for prolactin secretion. 
The effect of TRH on prolactin release and regulation will be discussed later. 
 
Plasma Concentration: 
 
The mean basal serum PRL of women is about 10 ng/ml, with an upper limit 
of normal of 20 ng/ml (360 mU/L) (25).  The mean plasma concentration in 
men and prepubertal children are slightly lower. 
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During sleep there is a rise in prolactin concentration.  It is particularly 
important to take samples for prolactin estimation at least 2 to 3 hours after 
waking to eliminate the misleading elevated levels found during sleep, and to 
remember that even the minor stress of venopuncture may cause prolactin 
secretion(18). 
 
Maternal levels of prolactin begin to rise in the first trimester of pregnancy 
and increase progressively to reach 100 to 300 ng/ml in the third trimester. 
 
After delivery, serum PRL progressively falls, reaching pregnant levels in 
two to three months in the absence of suckling.  If suckling does occur, 
afferent sensory nerves about the nipple initiate a reflex that causes a prompt 
secretary peak in prolactin secretion(26,27).  The perinatal secretion of prolactin 
is important in maintaining the lactational state and in delaying ovulation and 
the resumption of fertility.  As lactation proceeds, basal prolactin levels fall 
and the post suckling prolactin peak becomes less prominent.  Lactation is 
maintained because of increased sensitivity of the breast to these reduced post 
suckling peaks. 
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Test of PRL Secretion: 
 
1. PRL can be measured by radioimmunoassay or immunoradiometric 
assay.  If basal prolactin concentration is elevated, further evaluation is 
warranted after establishing that minimal prolactin elevations (e.g. less 
than 30 ug/L) are not stree-related.  Blood sampling from an indwelling 
catheter after a 90-minute rest period will exclude “needle stick”  
hyperprolactinaemia.  Although there is no simple test to distinguish the 
various causes of hyperprolactinaemia, serum prolactin level of over 300 
ug/L is diagnostic of a pituitary adenoma; a serum prolactin of over 100 
ug/L in a non pregnant patient is usually caused by a pituitary adenoma.  
Administration of dopamine agonists, such as bromocriptine, lowers 
prolactin regardless of the etiology and, therefore, is not useful as a 
differential test(19). 
2. TRH lactotropic cell stimulation: 100 ug TRH i.v. is administered and 
serum is obtained at 0, 15, and 30 minutes.  A three-to five fold increase 
in serum prolactin is normal.  Ninety percent of patients with 
prolactinoma have less than a two fold increase.  Patients with drug-
induced hyperprolactinaemia may also have impaired response to TRH. 
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3. Blockade of lactotropic cell dopamine receptors:  Domperiodene, 4 mg 
i.v. will cause > 200% increase in serum PRL in normal women.  
Impaired response occurs in patients with prolactinoma. 
4. Central blockade of dopaminergic pathways: Chlorpromazine 25 mg 
orally is administered and blood is obtained at 0.60, and 90 minutes.  
Normal response is greater than two fold rise in PRL.  Impaired response 
occurs in hypothalamic disease and prolactinomas.  Alternative agents 
with similar action include metoclopriamide, sulpiride and apomorphine. 
 
Prolactin Hypersecretion: 
Causes: 
1. Physiologic States 
a. Pregnancy 
b. Nursing (early) 
c. Stress 
d. Sleep  
e. Nipple stimulation 
 
II. Drugs 
a. Dopamine receptor antagonists 
i. Phenothiazines 
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ii. Butyrophenones 
iii. Thioxanthenes 
iv. Metoclopramide 
b. Dopamine – depleting agents 
i. Methyldopa 
ii. Resterpine 
iii. Climitidine 
c. Oestorgens 
d. Opiates 
III. Disease States 
a. Pituitary 
i. Prolactinomas 
ii. Adenomas secreting GH & PRI. 
iii. Adenomas secreting ACTH & 
iv. Non functioning chromphobe adenomas with stalk 
compression. 
 
b. Hypothalamic & pituitary stalk disease 
i. Granulomatus disease (e.g. Sacroidosis) 
ii. Craniopharngiomas 
iii. Cranial irradiation 
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iv. Stalk section 
v. Empty sella 
vi. Vascular abnormalities 
vii. Lymphocytes hypophysitis 
c. Primary hypothyroidism 
d. Chronic renal failure 
e. Cirrhosis 
f. Chest wall trauma (including surgery, herpes zoster) 
g. Seizures 
 
Before elaborate work-ups are undertaken, pregnancy should be ruled out and 
drugs that affect the dopaminergic pathways should be stopped for four to six 
weeks.  Co-existing hypothyroidism should be treated. 
Prolactinomas are the most common functional pituitary adenomas(28), and 
are the most important cause of hyperprolactinaemia(18).  They are almost five 
times more common in women than in men.  In women, two thirds of 
prolactinoimas are small.  Most patients present to physician in the third and 
fourth decade of life with menstrual disorders. 
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Clinical Manifestations of Hyperprolactinaemia: 
 
Prolactin excess acts through dopaminergic and opioid mechanisms on the 
hypothalamus to inhibit LHRH release and to cause hypogonadism(24).  The 
hormone also acts on the gonads, this action may contribute to the ovarian 
dysfunction of hyperprolactinaemic state. 
 
Patients may present with primary or secondary amenorrhoea.  Prolactinomas 
has been reported to occur in 13% of all women with secondary 
amenorrhoea(24).  And of women with amenorrhoea, 10 to 40 percent have 
hyperprolactinaemia(19).  About a third of patients with hyperprolatinaemia 
have galactorrhoea(18,24).  About a third of patients with hyperprolatinaemia 
have galactorrhoea(18,24).  In many cases this is not recognized by the patient 
and is demonstrated only after manual expression of milk from the breast by 
the physician. 
 
Most patients with galactorrhoea without amenorrhoea do not have 
hyperprolactinaemia. 
 
Galactorhoea is less common in men than women.  The reason for the relative 
infrequency of this disorder is presumably that appropriate oestrogen priming 
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of the breast is less common in men.  When galactorrhoea does occur in men, 
it is appropriate to evaluate patient both for feminizing syndrome and for 
prolactin excess. 
 
Prolactin excess in men can cause importance and infertility.  In some series 
8 percent of men with impotence and 5 percent of men with infertility have 
hyperprolactinaemia(19). With prolactin elevation, FSH and LH levels in men 
decline, and serum testosterone is often low. 
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HYPERPROLACTINAEMIA IN HHPOTHYROIDSIM 
 
After preparations of TRH were first shown by numerous investigations to be 
capable of releasing TSH in man.  Tashjian and coworkers, in 1970, made the 
surprising observation that TRH added to culture of rat pituitary tumour cells 
stimulated prolactin production(29). 
 
Subsequently it has been shown that bolus injections of microgram quantities 
of TRH in humans cause release of both TSH and prolactin(30,31,32),  and the 
question has been raised as to whether TRH might play a physiologic role in 
the control of prolactin as well as TSH secretion in man. 
 
Most investigations who have studied both TSH and prolactin release after 
TRH administration have reported that the smallest bolus of TRH capable of 
releasing TSH also released prolactin.  Thus, Jacobs et al, have reported that 
both TSH and prolactin responded to the smallest dose of  TRH they 
administered to 8 normal men, 6.25 ug(33).  And Bowers et al have reported 
simultaneous TSH and prolactin response to as little as 3 ug of TRH in 5 
normal women(34). 
Gantvik and coworkders have reported that 10 ug of TRH stimulated both 
TSH and prolatin release, whereas 1 ug of TRH stimulated neither(35). 
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Although these studies suggest that TRH is equally effective in releasing both 
TSH and prolactin in man, they all employed bolus injections of TRH which, 
because of the short half-life of TRH(36), results in a brief period of relatively 
high TRH concentration which is likely to be less physiologic than the 
smaller and sustained TRH elevations. 
Noel et al, employed continuous infusion of very small amounts of TRH and 
they found that, the smallest doses capable of producing an increase in 
circulating TSH also increase prolactin and that, sustained infusions of TSH 
produce sustained increases in circuating prolactin, TRH and T3, but 
maximal rates of prolactin secretion were achieved with TRH infusion rates 
considerably below those required for maximal prolactin release (37). 
On the other hand Shenkman, Mitsuma, and Hollander have reported that a 
single dose of 50 ug of oral T3 given 60 min before a TRH test completely 
abolished the TSH response to TRH (38) but failed to block prolactin release 
(39).  Bowers and coworkers have similarly reported that chronic 
administration of tiiodothyronine orally inhibited the TSH but not the 
prolactin response to standard TRH testing (34). 
As noted above, TRH is a potent PRL releasing factor (40) and as a result 
hyperprolactinaemia, due to TRH secretion, is common in primary 
hypothyroidism (41).  However, serum prolactin concentrations are only 
modestly elevated (2-3 times the upper limit of normal). 
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In their series of 24 patients with primary hypothyroidism, Sato et al (42) 
reported hyperprolactinaemia in 10 cases.  The maximum prolactin level 
reported by these authors was 236 mg/I (range 18 to 236 ug/L).  Because 
their patients were described as a group, it is not possible to determine the 
TSH levels corresponding to these prolactin elevations.  Sample et al (42,43) 
reported on a series of six patients with overt hypothyroidism.  The maximum 
prolactin level of 3800 ml/l (range, 590 to 3800 mU/L; normal 0 to 360 
mU/L) occurred in a patient with congenital hypothyroidism. 
In their series of 49 patients with overt primary hypothyroidism Honbo et al 
(44) reported hyperprolactinaemia in 19 patients.  the hyperprolactinaemia was 
modest, with a maximum prolactin level of 42 ug/I (normal < 14.0 ug/I).  in 
this group of patients, a logarithmic correlation was seen between prolactin 
and serum TSH levels. 
In a series of 16 female patients with overt primary hypothyroidism described 
by Onishi et al (45) ten had hyperprolactinaemia, with a maximum prolactin 
level of 89 ug/I in a patient with a TSH level of 1375 mU/I.  In this series 
there was a strong direct correlation between the magnitude of TSH elevation 
and the level of hyperprolactinaemia. 
All of the above cases of  hyperprolactinaemia were described in patients 
with overt hypothyroidism, but Olive and Hennesssey (46) described marked 
hyperprolactinaemia (187 ug/I, normal < 18 ug/L) in a patient with 
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subclinical hypothyroidism (TSH = 8 mU/L and T4 = 64 nmol/L).  
hyperprolactinaemia was normalized with levothyroxine therapy. 
Stanb JJ and coworkers investigated 86 female patients with the whole 
spectrum of subclinical hypothyroidism and of overt hypothyroidism.  They 
found a significant relationship between peak prolactin and basal TSH (9). 
Primary hypothyroidism may be presented with amenorrhoea, galactorrhoea, 
hyperprolactinaemia and enlarged pituitary which might suggest a prolactin-
secreting adenoma of the anterior pituitary gland. 
Actually, pituitary gland enlargement in primary hypothyroidism was first 
described by Boyce and Beadles in 1893(47).  Hyperplasia of the pituitary is 
common primary hypothyroidism and can be classified as involving both 
lacctotrophs and thyrotrops (more commonly observed) or isolated 
involvement of the thyrotrophs(48-50).  In long standing primary 
hypothyroidism pituitary adenomas may develop.  Such tumouls have been 
reported to be thyrotropic, mixed thyrotropic – lactotrophic or non-secretary 
types(51-53). 
In a combined histological and immunocytochemical study of 59 pituitary 
glands from patients with long-standing primary hypothyroidism, 12 pituitary 
adenomas were found(54).  Eight of these adenomas stained for TSH and/or 
prolactinm, one showed ACTH, but two adenomas failed to show any 
immuno-reactivity. 
 43
Ah Wah chan et al(55) reported on 2 young women with pituitary gland 
enlargement and hyperprolactinaemia (modest elevation) who were referred 
to a neurosurgical unit for consideration of pituitary surgery.  The 
presumptive diagnosis was a pituitary adenoma and both were found to have 
primary hypothyroidism.  Following thyroxine replacement treatment, the 
pituitary enlargement and hyperprolactinaemia completely resolved. 
Heyburne PJ and co-workers reported on a patient who presented with 
amenorrhoea, “galactorrhea, hyperprolactinaemia and suprasellar 
enlargement of the pituitary.  Although she was clinically euthyroid, her basal 
PRL and TSH were very high.  Treatment with L-thyroxine resulted in 
resolution of her symptoms and hormonal and radiological abnormalities 
within six weeks(50). 
Natori-S et al(56) also reported on a 37-year old housewife who presented with 
amenorrhoea, galactorrhoea and a pituitary enlargement that was shown by a 
CT scan.  She was proved to be suffered from primary hypothyroidism.  
Plasma TSH and prolactin concentrations returned to normal range in a few 
months after starting thyroid hormone replacement.  Furthermore, the finding 
of pituitary enlargement has completely disappeared on brain CT and the 
patient has come to pregnancy during the course. 
Ahmed and co-workers(57) studied 5 female patient with primary 
hypothyroidism and radiological evidence of a pituitary enlargement before 
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and with treatment with thyroxine.  Before treatment, TSH levels were 
elevated in every patient and prolactin levels in 4. During treatment with 
thyroxin, TSH and prolactin were normal in all.  Complete disappearance of 
the pituitary enlargement was seen on follow-up scans in all patients and one 
developed on empty sella. 
On the other hand, the principal inhibitor of PRL secretion, dompamine, also 
inhibits TSH(7,58,59). 
Elevated circulating levels of PRL resulting from a pRL-secreting pituitary 
tumour may induce the hypothalamus to produce excess dopamine in an 
attempt to inhibit PRL secretion(60).  Although this fails to inhibit PRL release 
from tumours, there may be inhibition of TSH secretion from thyrotrophs.  In 
a minority of individuals this suppression may be sufficient to cause a modest 
reduction in circulating T4 level i.e. secondary hypothyroidism. 
Decreased levels of TSH in PRL secreting adenoma might, as well, result 
from either destruction of the normal pituitary tissues, hypothalamic damage 
or compression of pituitary stalk(61). 
Hyperprolactinaemia with secondary hypothyroidism, though not common, 
must be distinguished from hyperprolactinaemia in primary hypothyroidism. 
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OBJECTIVES 
 
1. To detect the presence of hyperprolactinaemia in Sudanese 
hypothyroid patients. 
2. To assess the effect of L-Thyroxine therapy in normalixing the 
prolactin level. 
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PATIENTS AND METHODS 
 
Forty four patients with primary hypothyroidism were included in this study.  
Some of these patient were admitted in Khartoum and Elshaab Teaching 
Hospitals, some were selected from Endocrine referred clinics, and others 
were referred to the study from the Sudan Atomic Energy Commission. 
Both males and females were included in the study, males were 11 and 
females 33.   the underlying thyroid disorders of patients were as follows: 
autoimmune thyroiditis (5 patients), post-thyroidectomy (5 patients), and 
congenital (4 patients). 
The selection was performed on the basis of clinical suspicion of 
hypothyroidism, elevated TSH levels, low serum thyroxine level and absence 
of intake of drugs known to cause increase in serum prolactin.  All 
demographic data, symptomatology, physical findings and results of 
investigations were entered on a special form (Appendix 1). 
The clinical evaluation included: 
1- Patient characteristics: age, sex, occupation, residence. 
2- Symptoms related to hypothyroidism. 
3- Past medical history, family history and drug history, especially 
analyzing events related to thyroid problems. 
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The clinical examination included initial general examination with specific 
reference to features of hypothyroidism. 
The following investigations were carried out for all patients in the study: 
1. T4  2. TSH  3. PRL 
The following investigations were done for most of the patients (> 75%); 
1. Hb%  2.  ECG 
3. Chest x-ray 4.  Skull X-ray (lateral view) 
All the patients in the study had serum T4 levels in the hypothyroid range and 
basal TSH over to mU/I, and non of them had been receiving medication 
when first diagnosed. 
All patients were put on L-thyroxine therapy.  Follow up with T4, TSH and 
PRL levels was done for patients with an initial high PRL. 
Hormone measurement:  All were done in the Sudan Atomic Energy 
Commission. 
Total T4 (N. R.: 64 to 154 nmol/I) was measured by standard 
radioimmunoassay (RIA techniques using commercially available kits.  TSH 
(N.R: 0.5 to 3.5 mU/I; sensitivity of 0.04 mU/I) and PRL (N.R. 0 to 360 
mU.I) were measured by IRMA using commercially available kits.  
Measurement of the serum cholesterol was done in Elshaab hospital – main 
laboratory.  The total serum cholesterol was estimated by an enzymatic 
method. 
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Statistical analysis:  was done in a specialized computer center.  Data was 
computerized and analyzed by IBM/PC using SPSS.  Chi-Square test was 
used to analyze frequencies and Pearson’s linear regression model was used 
in correlation study and probability were obtained from data. 
The above mentioned tests were used to confirm significant differences in 
variables between patients with hyperprolactinaemia and patients with normal 
PRL. 
P value of 0.05 or less was considered to indicate statistical significance. 
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RESULTS 
 
 
 
Figure 1: Shows the age distribution of forty four patients included in this 
study.  Nine patients were below 15 years of age, 25 patients were to 45 
years old, and 9 patients were older than 45 years. 
Figure 2: Shows the sex distribution of the study group.    
Figure 3: Shows the age and sex distribution of patients; 50% of males 
were less than 15 years of age, and 73% were less than 30 years old. 
Figure 4: Shows the distribution of the study group according to the type 
of hypothyroidism.  Four patients (9%) had congenital hypothyroidism.  10 
(23%) had juvenile hypothyroidism, and 30 patients (68%) and adult 
hypothyroidism. 
Figure 5: Shows the distribution of patients according to the cause of 
hypothyroidism.  4 (9%) had congenital hypothyroidism, 5 (11%) developed 
hypothyroidism after thyroidectomy, 5 (11%) developed hypothyroidism 
after receiving medical treatment (radioactive iodine or antithyroid agent), 
and in 30 (68%) patients the cause was either chronic thyroiditis or 
idiopathic. 
Figure 6: Displays the frequency of symptoms in the study group.  
Fatigue and myalgia were the most frequently encountered symptoms, found 
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in 81% and 61% of cases respectively.  Constipation occurred in 43% of 
patients; goitre in 38% decreases auditory acuity and cold intolerance in 
36%; depression in 34% of patients; parathesia, poor memory and angina in 
32%, 27% and 20% respectively. 
Figure 7: Displays the frequency of clinical signs in the …. Proverty of 
movements and mental slowness were the most frequently observed signs, 
found in 77% and 75% of patient respectively.  Sixty eight percent were 
found to have puffy eyes.  Hoarseness of voice was noticed in 64%; the 
tendon jerks were hung-up in 61% of patients.  Dry sin, dry hair, and gross 
features were found in 57%, 55% and 48% of patients respectively.  Forty 
one percent had bradycarida and 36% were anaemia.  Thirty four percent 
had a large tongue and 23% had arcus and/or xanthoma.  The outer eye 
brows were lost in 18% of patients, and the same percentage of patients had 
signs of heart failure.  Visual field defect, carpal tunnel syndrome, and ataxia 
were found rarely.  Two patient had an associated autoimmune disease, and 
one patient presented with psychosis. 
Table 1: Shows  a comparison between the frequency of clinical features 
in this study and the frequency of clinical features in Means JH study. 
Table 1 and Figure 8: Shows the frequency of hyperprolactinaemia in 
patients with hypothyroidism.  14 (42%) of 33 women and 5 (45%) of 11 
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men had high PRL (P=0.86).  The Total number of patients with 
hyperprolactinaemia – out of 44 hypothyroid patients is 19 (43%). 
Table 3: Shows the details of 19 hypothyroid patients with 
hyperprolactinaemia. Age range (1 to 56 years); 14 females 5 males.  The 
causes of hypothyroidism were: congenital in 3 patients …………….. 
treatment in 3 patients, and the cause was chronic hypothyroidism …… in 
13 patients.  galactorrhoea was found in 4 ranged between 400 and 1959 
mU/I (mean 877 mU/I).  T4  between 4 and 36 nmol/l (mean 16 nmol/I); 
TSH ranged between mU/I).  three patients were found to have enlarged 
sella on the lateral skull X ray. 
Figure 9:  shows the incidence of hyperprolactinaemia in hypothyroid 
patients, according to the cause of hypothyroidis.  It occurred in 13 (43%) 
out of 30 patients who had idiopathic or chronic thyroiditis.  Three (75%) 
out of 4 patients with congenital hypothyroidism had high PRL; while 3 
(30%) out of 10 patients – who developed hypothyroidism after 
thyroidectomy or receiving medical treatment had high PRL. (P= 0.43 
Figure 11:  shows the incidence of hyperprolactinaemia in hypothyroid 
patient according to the type of hypothyroidism.  12 (40%) out of 30 patients 
with adult hypothyroidism had high PRL; 4 (40%) out of 10 patients with 
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juvenile hypothyroidism had hyperprolactinaemia, while 3 (75%) out of 4 
patients with congenital hypothyroidism had high PRL.  (P=0.4) 
Figure 12 a & b:  shows the relation between serum prolactin and TSH 
level sin hypothyroid patients with hyperprolactinaemia.  A positive 
correlation was observed. 
Figure 13 and Table 4:  Compare the PRL level 3 months after treatment to 
the initial PRL level in patients with hyperprolactinaemia.  All patients 
whose initial PRL in the range 360-500 normalized.  Three of 8 patients with 
PRL in the range 500-1000 normalized, the other 5 patients had a 
considerable reduction in the PRL level.  One of 5 patients with an initial 
PRL level above 1000 mU/I normalized; the remaining 4 had a considerable 
reduction in the PRL level. (P=0.03) 
Figure 14:  shows the frequency of ECG changes in hypothyroid patients in 
different age groups.  Two of 8 patients aged 0-15 years had ECG changes.  
Three of 10 aged 16-30 had ECG changes.  Eight of 12 aged 31-45 and 5 of 
6 patients aged 46-60 had ECG changes.  All the 3 above 60 years – in this 
study had ECG changes. (P=0.53) 
Figure 16:  shows the frequency of CXR changes in hypothyroid patients in 
different age groups. (P=0.05) 
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Figure 17:  shows the frequency of CXR changes in patients with high PRL 
in comparison to the frequency of CXR changes in patients with normal 
PRL.  31% of patient with high PRL had abnormal CXR (5 patients had 
cardiomegaly and one patient had pleural effusion), while 20% of patients 
with normal PRL had cardiomegaly on CXR. (P=0.42) 
Figure 18:  shows the mean serum cholesterol levels in hypothyroid patients 
compared to the mean serum cholesterol in the normal population, in 
different age groups.  The normal mean serum cholesterol in the age group 
0-20 years in 160 mg/dl(62),  while the mean value is 195 mg/dl; the figure is 
195 in hypothyroid patients.  In the age group 20-40 the normal is 165 
mg/dl; the figure is 195 in hypothyroid patients.  In the age group 40-60 the 
normal mean level is 170 mg/dl; it was found to be 205 mg/dl in the study 
group.  For patients above 60 years the normal is 175 mg/dl; in the study 
group the mean value was 200 mg/dl.  There was a significant increase in the 
serum cholesterol in all age groups of hypothyroid patients. 
Figure 19:  shows the relationship between TSH level and the mean serum 
cholesterol in hypothyroid patients. Four patients with TSH less than 15 
mU/I the mean serum cholesterol was 170 mg/dl.  For those with TSH level 
between 15 and 50 mU/I the mean serum cholesterol was 173 mg/dl.  For 
patients who had TSH between 50 and 100 mU/I, cholesterol was 232 mg/dl, 
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and for those with TSH between 50 and 100 mU/I, cholesterol was 232 
mg/dl, and for those with TSH between 100 and 150 mU/I, mean serum 
cholesterol was 235 mg/dl.  Serum cholesterol was 238 mg/dl for patients 
with TSH above 150 mU/I. (P=0.045) 
Figure 20:  shows the relationship between prolactin level and mean serum 
cholesterol in the study group. (P=0.44) 
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DISCUSSION 
 
The relationship between pituitary prolactin secretion and primary 
hypothyroidism has been extensively reviewed.  There is evidence that PRL 
secretion is modified in all patients with primary hypothyroidism, some of 
them present with frank hyperprolactinaemia, the others present with 
enhanced PRL  release after TRH administration(62,63). 
Hyperprolactinaemia is common in hypothyroidism. The estimated 
frequency of hyperprolactinaemia among patients with hypothyroidism 
ranged from 30% of more than 60% of cases, in most of the previous 
studied(9,42-45).  Some workers reported normal prolactin levels in series of 
hypothyroid patients(64-67) but all of these studies involved a small groups of 
patients. 
In the forty four patients included in this study, 19 (43%) were found to have 
a high prolactin levels, a figure which is in agreement with those reported 
earlier. 
In this study hyperprolactinaemia ranged from mild to moderate.  The 
maximum PRL level observed was 1959 mU/I (range 400-1959 mU/I).  this 
magnitude of hyperprolactinaemia is in keeping with results reported by 
others(42-45). 
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In this study a positive correlation was observed between basal TSH and 
PRL level. 
A positive correlation between TSH and PRL was demonstrated by Onishi et 
al(45) and Honbo et al(44) in their results, while Gautvik et al(68) and Littermite 
et al(69) found no correlation between PRL and TSH level in primary 
hypothyroidism. 
The relationship between the age and incidence of hyperprolactinaemia was 
studied.  hyperprolactinaemia was found in 67% of patients below 15 years 
of age, while 44% of patients between 16 and 45 years had 
hyperprolactinaemia, and only 20% of patients older than 45 years had high 
PRL (P = 0.27, which is not statistically significant). 
In earlier studies no relationship between age and incidence of 
hyperprolactinaemia was noted(44,70).  Others, however noted a general 
decline in serum prolactin levels with increasing age(71,72), whereas another 
report showed an increase in serum PRL in men after age 45(73).  In this 
study the only male above 45 years had a high PRL. 
The relationship between sex and the incidence of hyperprolactinaemia was 
studied as well.  Fourteen of 33 (42%) women and 5 of 11 (45%) men had 
hyperprolactinaemia (P = 0.86).  There is no significant difference in the 
incidence of hyperprolactinaemia between males and females.  This 
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contrasts with the findings in the 49 patients included in Honbo et al(44) study 
where 17 of 39 (44%) women and two of 10 (20%) men had high PRL 
levels, they, also stated that the mean serum PRL in the hypothyroid women 
was significantly higher than the mean serum PRL in the hypothyroid men/ 
Three month after starting L-thyoxine therapy, PRL was found to be much 
reduced in all patients who had an initial high PRL.  This confirmed that 
hyperprolactinaemia was solely resulted from the hypothyroid state, and that 
it is acceptable with thyroxine treatment alone.  This is similar to results 
reported by Heyburn et al(50),  Ah Wah et al(55), Natori et al(56), and Ahmed et 
al(57).  
Galactorrhoea were females in the age group 25-35 years.  Four of them had 
high prolactin and two with normal PRL level.  Galactorrheoa resolved and 
the PRL levels dropped in all but one patient.  In the latter, galactorrhoea 
stopped temporarily on commencing L-thyroxine treatment, but soon 
recurred and persisted despite the fact that, the patient had become 
euthyroid. 
The above results are in keeping with previous studies and observations that 
galactorrhoea is less common than hyperprolactinaemia and that 
galactorrhoea with primary hypothyroidism is associated with either high or 
normal circulating levels of prolactin(41,74-76). 
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Other signs and symptoms of hypothyroidism were, also, studied and the 
incidence of each symptom and sign was estimated.  The results were 
compared with the results reported by Means JH(16).  The major differences 
observed in the following: 
Dry skin found in 97% of cases in Means JH study and in only 55% in this 
study.  Sensation of cold occurred in 89% in the old study and, only, in 34% 
of patients in this study.  Gain in weight was estimated in a frequency of 
59% of patients in Means JH study.  Only 7% of patients noticed gain in 
weight in the present study.  The frequency of occurrence of other symptoms 
were, some what, comparable, but, generally, most of the features occurred 
with less frequency in Sudanese patients.  Table (1) compare the frequencies 
of clinical features in the two studies.  However, the comparison is not very 
accurate because the old study included only myxoedema patients, while this 
study included some patients with congenital and juvenile hypothyroidism 
who might not developed the full-blown picture of myxoedema. 
Hung-up tendon jerks was detected in more than 60% of patients. actually, 
this sign was the clue to the diagnosis in two patients included in this study.  
Although can be seen in other medical conditions, delayed relaxation of 
tendon jerks seems to be a reliable and important sign in hypothyroidism. 
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The frequencies of occurrence of clinical signs and symptoms were 
compared in hypothyroid patients with normal PRL and patients with high 
PRL.  No significant differences were observed. 
The study also confirms the well known relationship between 
hyperprolactinaemia hypothyroidism.  The mean serum cholesterol for each 
age group of hypothyroid patients was compared to serum cholesterol in the 
same age group in the general population (62).   In the study group the mean 
serum cholesterol levels were higher in all age group, and while in the 
normal population the mean serum cholesterol increased with age, the 
positive relationship between serum cholesterol level and age was lost in 
hypothyroidism. 
Mean serum cholesterol was compared to TSH level.  A positive correlation 
was found (P=0.45).  this confirms the observation by Kully M. et al (21) that 
a graded increase in mean serum cholesterol related to increased levels of 
serum TSH but not to age was observed as thyroid failure increases. 
The mean serum cholesterol was compared to prolactin level (P-0.44), no 
relation can be demonstrated. 
ECG was done for most of the patients included in the study.  In 43% of 
them, some ECG changes like low voltage and ST-T changes were found.  
ECG changes were ore frequently encountered in older ages (P=0.02). 
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The frequency of ECG changes in patients with hyperprolactinaemia was 
compared to that in patients with normal PRL level, no significant difference 
can be noticed (P=0.53).  These findings suggest that, the increased 
frequency of ECG changes in hypothyroid patients is related to the 
hypothyroid state as well as to the age of the patient and not to PRL. 
The study also confirms the fact that chest X-ray findings especially 
cardiomegaly are common in hypothyroidism.  Ten patients (23%) had 
cardiomegaly and one patient had pleural effusion.  Forty percent of patients 
older than 45 years had cardiomegaly, while only 18 percent of patient 
younger than 45 years had cardiomegaly (P=0.05).  On the other hand, 5 
patients (26% with hyperprolactinaemia and 5 patients (20%) with normal 
PRL had cardiomegaly (P=0.42).  These results suggest that the increased 
incidence of cardiomegaly in hypothyroid patients is influenced by both the 
age and the hypothyroid state.  Prolactin level has no significant relationship 
to the incidence of chest X-ray changes. 
In conclusions:  this study underlines the fact that hyperprolactinaemia is 
common in primary hypothyroidism, and it is correctable with L-thyroxine 
therapy. 
It is recommended that, thyroid function tests be obtained in all patients with 
hyperprolactinaemia. 
 86
REFERENCES 
 
(1) Ingbar SH. The thyroid gland, In: William RH, editor.  Text Book 
of Endocrincology, 7th ed. Philadelphia; W.B. Saunders: 1985.p. 
682-815.   
(2) Hagerstown MD.  The Thyroid. In: Werner SC, Ingbar SH, eds.  
London; Harper & Row: 1978.p. 206-215. 
(3) Berkowitz M, Daughtridge D, Sherwin JR. Autoregulation of 
thyroid iodide transport: Possible mediation by modification in 
sodium cotrasport. Am J Physiol 1981; 240: E37-E42. 
(4) Greer MA, Halback H. Thyroid secretion. In: Greer MA, Solomon 
DH, eds. Handbook of Physiology, Sec 7: Endocrinology. vol 3, 
Thyroid. Baltimore; William & Wilkins: 1974.p. 135-146. 
(5) Stockight JR, Degaris M, Csicsmann J. Limitation of a new free 
thyroxine assay (Amerlex free T4). Clinical Endocrinol 1981; 15: 
313-18. 
(6) Ingbar SH, Borges M. Peripheral metabolism of thyroid hormones: 
Free thyroid hormones. Experta Medica 1979; 17:27. 
(7) Morely JE. Endocrine control of thyroid secretion. Endocr Rev  
1981; 2: 396-436. 
(8) Greer MA, Solomon DH, eds. Handbook of physiology, sect 7: 
Endocrinology. Vol 3. Thyroid. Baltimore; Williams & Wilkins: 
1974.p. 377-468. 
(9) Staub JJ, Althaus BU, Engler H, Ryff AS. Spectrum of subclinical 
and overt hypothyroidism. Am J Med1992; 92: 631-42. 
 87
(10) Tunbridge WMG, Evered DC, Hall R. The spectrum of thyroid 
disease in a community: The Which ham survey. Clin Endocrinol 
1977; 7: 481-93. 
(11) Gordin A, Lamgerg BA. Natural course of symptomless 
autoimmune thyroiditis. Lancet 1975; 2: 1234-238. 
(12) Lee JK, Lewis JA. Myxoedema with complete A-V block and 
Adams-Stokes disease abolished with thyroid medication. Br Heart 
J 1962; 24: 253-56. 
(13) Rothman NP. Neurological and muscular aspects of thyroid 
dysfunction in childhood. Pediatr Clin North Am 1976; 23: 575-
94. 
(14) Carmel A, Spencer CA. Clinical and subclinical thyroid disorders 
associated with pernicious anaemia. Arch Intern Med 1982; 142: 
1465-469. 
(15) Distiller LA, Sagel J, Morley JE. Assessment of pituitary 
gonadotropin reserve using LHRH in states of altered thyroid 
function. J Clin Endocrinol Metab  1975; 40: 512. 
(16) Means JH. The thyroid and its diseases. N Williams RH, editor.  
Textbook of Endocrinology, 7th ed. Philadelphia; J.B. Lippicott: 
1985.p.233. 
(17) Lobo E DeH, Khan M, Tew J. Community study of 
hypothyroidism in Down’s syndrome. Br Med J 1980; 280: 1253. 
(18) Joan F, Zilva, Peter R, Pannall  S,  Philip D. Mayne Z. Clinical 
Chemistry of Diagnosis and Treatment, 5th ed. Chapter 8. London; 
S. B. Saunders: p. 167-170. 
 88
(19) Leonard Wartofsky, Sidney H. Ingbar. Diseases of the thyroid. In: 
Harison’s Principals of Internal Medicine, 12th ed.  London; 
Martin Dunitz Ltd:  1985.p. 1692-1712. 
(20) Jenkins DJ. An investigation into creatine kinase and other plasma 
enzymes in thyroid disorders. Clin Chim Acta  1978; 85: 197-204. 
(21) Kutty M. Kutty, David C. Bryant and Nadir R. Farid. Clin 
Endocrinol Metab 1978; 46: 55. 
(22) Revani I, DiGeorge AM. Reassessment of the daily dose of oral 
thyroxine for replacement therapy in hypothyroid children.  J 
Pediatr  1977; 90: 291-297. 
(23) Abassi V, Adigi C. Evaluation of sodium L-thyroxine (T4) 
requirement in replacement therapy of hypothyroidism.  J Pediatr 
1977; 90: 298-301. 
(24) William H Dughaday. The anterior pituitary. In: Williams RH, 
Textbook of Endocrinology. 7th ed. Philadelphia; W.B. Saunders: 
1985: p. 568-613. 
(25) Jacobs LS, Mariz IK, Daughaday WH. A mixed heterologous 
radioimmunoassay for human prolactin.   J Clin Endocrinol Metab 
1972; 34: 484-90. 
(26) Frantz AG. Prolactin. N Engl J  Med 1978; 298: 201-07. 
(27) Noel GL, Suh HK, Frantz AG. Prolactin release during nursing and 
breast stimulation inpostpartum and non-postpartum subjects.   J 
Clin Endocrinol Metab  1974; 38: 413-23. 
(28) Nabarro JDN. Review. Pituitary prolactinomas. J Clin Endocrinol 
Metab 1982; 17: 129-56. 
(29) Tashjian AH, Barowsky NJ, Jensen DK. Biochem Biophys Res 
Commun 1971; 43: 516. 
 89
(30) Bowers CY, Friesen HG, Hwang P, Guyda HJ, Folkers K. 
Biochem Biophys Res Commun 1971; 45: 1033. 
(31) Jacobs, LS, Snyder PJ, Wilber JF, Utgaer RD, Daughday WH. J 
Clin Endocrinol Metab 1971; 33: 996. 
(32) L’Hermite ML, Vanhaelst G, Copinschi R, Leclerq J. Golstein OD. 
Robyn C, et al. Lancet 1972; 1: 763. 
(33) Jacobs LS, Snyder PJ, Utiger RD, Daughaday WH. J Clin 
Endocrinol Metab 1973; 36: 1069. 
(34) Bowers CY, Friesen HG, Folkers K. Biochem Biophys Res 
Commun 1973; 51: 512. 
(35) Gautvik KM, Weintraub BD, Graeber CT,  Maloof F, Zuckerman 
JE, Tashian AH. J Clin Endocrinol Metab 1973; 36: 135. 
(36) Bassiri RM, Utigr RD. J Clin Invest  1973; 52: 1616. 
(37) Noel GL, Richard C, Dimond T, Wartofsky L, Jerry M, Andrew G, 
et al. J Clin Endocrinol Metab 1974; 39: 6-17. 
(38) Shekman L, Mitsuma T, Hollander CS. J Clin Invest  1973: 52: 
205. 
(39) Katoaka K, Imai Y, Shenkman L, Hollander CS. J Clin Res  1973; 
21: 494. 
(40) Jackson IMD. Thyrotropin-Releasing Hormone. N Engl J Med 
1982; 306: 145-55. 
(41) Edwards CRW, Forsyth IA, Besser GM. Amenorrhoea, 
galactorrhoea and primary hypothyroidism with high circulating 
levels of prolactin. Br Med J 1971; 3: 462-64. 
(42) Sato S, Hanew K, Sassaki A. Enhanced prolactin secretion in 
patients with primary hypothyroidism during thyroid replacement. 
Tohoku J Exp Med 1984; 144: 425-31. 
 90
(43) Semple CG, Beastall GH, Teasdale G. Hypothyroidism presenting 
with hyperprolactinaemia. Br Med J 1983; 286: 1200-201. 
(44) Honbo KS, Van Herle AJ, Kellett KA. Serum prolactin levels in 
untreated primary hypothyroidism. Am J Med 1978; 64: 782-87. 
(45) Onishi T, Miyai K, Aono T. Primary hypothyroidism and 
galactorrhoea. Am J Med 1977; 63: 373-78. 
(46) Olive KE, Hennessey JV. Marked hyperprolactinaemia in 
subclinical hypothyroidism. Arch Intern Med 1988; 148: 2278-279. 
(47) Boyce R, Beadle CF: Enlargement of the hypophysis cerebri in 
myxoedema. J Pathol Bacteriol 1893; 1: 223-39.  
(48) Grubb MR, Chakeres D, Malarkey WB. Patients with primary 
hypothyroidism presenting as prolactinomas. Am J Med 1987; 83: 
765-69. 
(49) Poretsky L, Garber J, Kleefield J. Primary amenorrhoea and 
psudoprolactinoma in a patient with primary hypothyroidism. Am J 
Med 1986; 81: 180-82. 
(50) Heyburn PJ, Gibby OM, Hourihan M, Hall R, Scanlon MF. 
Primary hypothyroidism presenting as amenorrhoea & 
galactorrhoea with hyperprolactinaemia and pituitary enlargement. 
BMJ 1986: 292: 1660-661. 
(51) Gup RS, Sheeler LR, Maeder MC. Pituitary enlargement and 
primary hypothyroidism: A report of two cases with sharply 
contrasting outcomes. Neurosurgery 1982; 45: 903-11. 
(52) Samaan NA, Osborne BM, Mackay B. Endocrine and morphologic 
studies of pituitary adenomas secondary to primary 
hypothyroidism: J Clin Endocrinol Metab 1977; 76: 725-28. 
 91
(53) Fatourechi V, Gharib H, Meybody NA, Gharib M. Pituitary 
thyrotropic adenoma associated with congenital hypothyroidism. 
Am J Med 1984; 67: 725-28. 
(54) Scheithauer BW, Kovacs K, Randall RV, Ryan N. Pituitary gland 
in hypothyroidism. Arch Path Lab Med 1985; 109: 499-504. 
(55) Wah AH, Ian A, Macfarlane Y, Patrick M, John B. Pituitary 
enlargement and hyperprolactinaemia due to primary 
hypothyroidism. Neurosurgery 1990; 4: 107-112. 
(56) Natori S, Karashima T, Koga S. A case report of iodiopathic 
myxoedema with secondary amenorrhoea and 
hyperprolactinaemia. Fukuola-Igaku-Zasshi 1991: 82: 461-63. 
(57) Mahmmed Ahmed, Mohammed Banna, Nadia Sakati, Nicholas 
Woodhouse. Pituitary gland enlargement in primary 
hypothyroidism: A report of 5 cases with follow-up data. Horm 
Res 1989; 32: 188-92. 
(58) Reichlin S. Neuroendocrinology. In: Williams RH, editor. 
Textbook of Endocrinology, 7th ed. Philadelphia: W.B. Saunders; 
1985.p. 215-220. 
(59) Holdaway M, Evans MC, Sheehan A, Ibbertson HK. Low 
thyroxine levels in some hyperprolactinaemic patients due to 
dopaminergic suppression of thyrotropin. J Clin Endocrinol Metab 
1984; 59: 608-13. 
(60) Scanpm MF, Pourmand M, McGregor AM. Some current aspects 
of clinical and experimental neuroendocrinology. J   Endocrinol 
Invest  1979: 2:  307. 
 92
(61) Tadmor OP, Barr I, Diamant YZ. Primary hypothyroidism 
presenting with amenorrhoea, galactorrheoa, hyperprolactinaemia 
and enlarged pituitary. Harefuah 1992; 122: 76-8. 
(62) Schlant RC, Digirolamo M. Modification of risk factors in the 
prevention and management of coronary atherosclerotic heart 
disease. In: Willis H J. editor.  The Heart, 4th ed. New York, NY; 
McGraw-Hill: 1978.p. 1316. 
(63) Hyperprolactinaemia in hypothyroidism: effect of L-thyroxine 
therapy. Minerva Endocrinol 1994; 19(1): 1-4. 
(64) Bowers CY, Friesen HG, Hwang P. Prolactin and thyrotropin 
release in man by synthetic pyroglutamyl-histidyl-prolinamide. 
Biochem Biophys Res Commun 1971; 45: 1033. 
(65) Snder PF, Jacobs LS, Utiger RD. Thyroid hormone inhibition of 
the prolactin response to thyrotropin-releasing hormone. J Clin 
Invest 1973; 52: 2324. 
(66) Tolls G, Somma M, Van Campenhout J. Prolactin secretion in 
sixty-five patients with galactorrhoea. Am J Obstet Gynaecol 1974; 
118: 91. 
(67) Fossati PL, Hermite M, Derrien G. La Prolactinemic chezles 
myxoedemateuses. Ann Endocrinol 1975; 36: 145. 
(68) Gautvik KM, Weintraub BD, Graeber CT. Serum prolactin and 
TSH: Effect of nursing and pyroGlu-His-Parol administration in 
postpartum women. J Clin Endocrinol Metab 1973; 36: 135. 
(69) Yamaji T. Dodulation of prolactin released by altered levels of 
thyroid hormones. Metabolism 1974; 23: 745. 
(70) L’Hermite M, Robye C, Goldstein J. Prolactin and thyrotropin in 
thyroid disease: Lack of evidence for a physiological role of 
 93
thyrotropin-releasing hormone in the regulation of prolactin 
secretion. Horm Metab Res 1974; 6: 190. 
(71) Schmidt-Gollwitzer M, Saxena BB: Radioimmunoassay of human 
prolactin. Acta Endocrinol 1975; 80: 262. 
(72) Birkoff JD, Lattimer JK, Frantz AG. Role of prolactin in benign 
prostatic hypertrophy. Urology 1974; 4: 557. 
(73) Vekemans M, Robyne C: Influence of age on serum proalctin 
levels in women and men. Br J Med 1975; 4: 738. 
(74) Kleinberg DL, Noel GL, and Frantz AG. Galactorrhoea. A study of 
235 cases, including 48 with pituitary tumors. N Engl J Med 1977; 
296: 589-600. 
(75) Macaron C. Galactorrhoea in post-thyroidectomy patients. Arab J 
Med 1984; 3(8): 12-3. 
(76) El Mahdi MA, Mukhtar E, Abdelrahman MH. Galactorrhoea and 
primary hypothyroidism: Report of two cases from Khartoum. 
Ethiop Med J 1986: 24: 97-9. 
 
 
 55
RESULTS 
 
Table  1 
Clinical Picture of Hypothyroidism 
Comparison between Means JH Study & the Present Study 
 
Symptoms  Sign Means JH Study The Present Study 
 of Cases of Cases 
Weakness 99 82 
Dry skin 97 55 
Coarse skin 97 55 
Lethargy 91 72 
Oedema of eyelids 90 68 
Sensation of cold 89 34 
Thick tongue 82 34 
Coarseness of hair 76 55 
Memory impairment 66 30 
Constipation 61 39 
Gain in weight 59 7 
Dyspnoea 55 20 
Peripheral oedema 55 16 
Hoarseness or aphonia 52 60 
Anorexia 45 34 
Menorrhagia 32 11 
Deafness 30 34 
Pericardial pain 25 18 
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Table  2: 
Hyperprolactinaemia in Hypothyroidism 
 
 
 
PRL Male % Female % Total % 
High 5 45 14 42 19 43 
Normal 6 55 19 58 25 57 
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Table  3: 
 
Details of 19 Hypothyroid Patients with Hyperprolactinaemia 
 
Age Sex Cause of  Galactorrhoea TSH 
mU/L
PRL 
(mU/L) 
T4 
(nmol/L
  Hypothyroidism Setta     
1 F C No No 154 800 6 
7 M C No No 183 900 7 
9 M C No No 113 714 19 
11 F I No No 204 800 7 
13 F I  No 87 1061 9 
14 F PT No No 197 900 9 
24 M I No No 210 950 38 
25 F I No No 24 400 55 
26 F I No Yes 56 1950 10 
29 F I Yes No 210 1248 9 
30 F I  No 89 733 13 
32 F PT No No 28 1008 20 
35 F I No Yes 89 1070 9 
35 M I Yes No 82 700 6 
35 F I Yes No 85 600 18 
35 F I No Yes 90 750 14 
38 F I No Yes 50 550 9 
50 F I No No 83 885 19 
56 M PT No No 89 645 19 
Average   No No 112 877 16 
 
 
Congenital  I = Idiopathic  PT = Post Treatment 
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Table  4: 
 
Last PRL Level in Relation to the Initial PRL level in 19 
Hypothyroid Patients with Hyperprolactinae 
 
Initial serum Last serum level (mU/L 
PRL range (mU/L) Normalized Improved Not changed 
360-500 6 0 0 
500-1000 3 5 0 
1000-1500  1 3 0 
> 1500 0 1 0 
Total 10 9 0 
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